- Page 3: Clinical Practice Guidelineon Atten
- Page 8 and 9: AppendicesAppendix 1 Levels of evid
- Page 10 and 11: We trust that this work will undoub
- Page 12 and 13: Jesús Eirís Puñal, neuropaediatr
- Page 15 and 16: Questions to be answeredADHD1. How
- Page 17 and 18: 39. In which ADHD subtypes is pharm
- Page 19 and 20: Recommendations of the CPG<
- Page 21 and 22: 6. Assessment instruments6.1. Which
- Page 23 and 24: 7.2.3. Pyschopedagogical re-educati
- Page 25 and 26: 7.3.7. In ADHD: How long should the
- Page 27 and 28: 7.3.13. What scientific evidence ex
- Page 29 and 30: B 7.5.3.2.In children and adolescen
- Page 31 and 32: 9.4. How involved must the minor be
- Page 33 and 34: 1. IntroductionBackgroundThe “Evi
- Page 35 and 36: Table 1. ADHD prevalence studies in
- Page 37: Health RepercussionsThe repercussio
- Page 40 and 41: Secondary objectivesa) To generate
- Page 42 and 43: • Formulation of clinical questio
- Page 44 and 45: evidence have been solved by consen
- Page 46 and 47: ment.At school age, the hyperactive
- Page 48 and 49: Volumetric brain studies have shown
- Page 50 and 51: 4.4. What is the natural course of
- Page 52 and 53: Parents’ psychopathologyIn the st
- Page 55 and 56:
5. DiagnosisQuestions to be answere
- Page 57 and 58:
A SR conducted by the NICE guidelin
- Page 59 and 60:
Family backgroundSummary of scienti
- Page 61 and 62:
5.4. In the diagnosis of ADHD in ch
- Page 63:
5.7. In the diagnosis of ADHD in ch
- Page 66 and 67:
6.1. Which screening instruments an
- Page 68 and 69:
Title Authors Year Description Age
- Page 70 and 71:
Title Authors Year Description Age
- Page 72 and 73:
RecommendationsC 6.1.1. 6.1.2. 6.2.
- Page 74 and 75:
6.5. In ADHD in children and adoles
- Page 77 and 78:
7. Treatment7.1. Psychological trea
- Page 79 and 80:
Variable: ADHD symptomsScientific e
- Page 81 and 82:
Variable: Internalized symptomsScie
- Page 83 and 84:
The scientific evidence about the e
- Page 85 and 86:
Variable: Social skillsScientific e
- Page 87 and 88:
7.1.4. How effective is the psychol
- Page 89 and 90:
7.2. Psychopedagogical TreatmentQue
- Page 91 and 92:
• Working on habits that foster a
- Page 93 and 94:
Teacher’s adaptationsScientific e
- Page 95 and 96:
Scientific evidenceThere is not suf
- Page 97 and 98:
7.3. Pharmacological treatmentQuest
- Page 99 and 100:
to proteins is 15% and there are no
- Page 101 and 102:
AtomoxetineThis is a non-stimulant
- Page 103 and 104:
7.3.2. In ADHD: What pharmacologica
- Page 105 and 106:
There is strong scientific evidence
- Page 107 and 108:
Variable: Behavioural problemsScien
- Page 109 and 110:
There is not sufficient scientific
- Page 111 and 112:
BupropionThe NICE CPG</stro
- Page 113 and 114:
There is not sufficient scientific
- Page 115 and 116:
Summary of the scientific evidence
- Page 117 and 118:
7.3.4. In ADHD: When and with what
- Page 119 and 120:
MethylphenidateSummary of the scien
- Page 121 and 122:
AtomoxetineSummary of the scientifi
- Page 123 and 124:
The consensus of the American Heart
- Page 125 and 126:
In a RCT that studied the efficacy
- Page 127 and 128:
7.3.13. What scientific evidence ex
- Page 129 and 130:
7.3.15. Does the efficacy of pharma
- Page 131 and 132:
Recommendations 7.3.17.1. 7.3.17.2.
- Page 133 and 134:
Scientific evidenceThe scientific e
- Page 135 and 136:
There is not sufficient scientific
- Page 137 and 138:
There is not sufficient scientific
- Page 139 and 140:
There is limited scientific evidenc
- Page 141 and 142:
The combined intervention of MTA is
- Page 143 and 144:
There is limited scientific evidenc
- Page 145 and 146:
There is not sufficient scientific
- Page 147 and 148:
The scientific evidence of Zupancic
- Page 149 and 150:
RecommendationsC 7.5.1.1.The use of
- Page 151 and 152:
Summary of the scientific evidenceT
- Page 153 and 154:
Summary of the scientific evidenceT
- Page 155 and 156:
Elimination interventions include t
- Page 157 and 158:
Auditory stimulationThis is based o
- Page 159:
8. PreventionGiven the mainly genet
- Page 162 and 163:
Recommendations 9.1.1.In the specif
- Page 164 and 165:
Recommendations 9.4.1.Applicableleg
- Page 166 and 167:
10. Diagnostic and therapeutic stra
- Page 168 and 169:
Algorithm 3. Pharmacological treatm
- Page 171 and 172:
11. Dissemination and implementatio
- Page 173 and 174:
12. Future research recommendations
- Page 175:
home, at school or in the recreatio
- Page 178 and 179:
Appendix 1: Evidence levels and rec
- Page 180 and 181:
Impulsivitya) Often blurts out answ
- Page 182 and 183:
Appendix 3. Information for patient
- Page 184 and 185:
3. How does ADHD evolve with age?In
- Page 186 and 187:
5.1. Psychological treatment for AD
- Page 188 and 189:
What drugs are available in Spain?A
- Page 190 and 191:
Is pharmacological treatment for AD
- Page 192 and 193:
10. What can be done from school to
- Page 194 and 195:
Appendix 4. GlossaryAGREE: Instrume
- Page 196 and 197:
and mental operations, self-regulat
- Page 198 and 199:
tions that are to be compared.The r
- Page 200 and 201:
Appendix 5. AbbreviationsAACAPAAPAD
- Page 202 and 203:
MAMFF_20mgMHSMSCAMTA StudyNICENIMHN
- Page 204 and 205:
Appendix 6. Declaration of interest
- Page 206 and 207:
Alicia Koplowitz Foundation, Jansse
- Page 208 and 209:
Health Care Guideline: Diagnosis an
- Page 210 and 211:
Attention deficit hyperactivity dis
- Page 212 and 213:
tionario de Conners en nuestro medi
- Page 214 and 215:
50. Quinn P, Wigal S. Perceptions o
- Page 216 and 217:
twin study: preliminary report. 199
- Page 218 and 219:
Number 3, August 1999. Agency for H
- Page 220 and 221:
controlled trial of integrated home
- Page 222 and 223:
Improvement. Clinical Practice Guid
- Page 224 and 225:
Adolesc Psychiatry. 2006 Nov;45(11)
- Page 226 and 227:
Acad Child Adolesc Psychiatry. 1995
- Page 228 and 229:
omized, double-blind, placebo-contr
- Page 230 and 231:
300. Wilens TE, Newcorn JH, Kratoch
- Page 232 and 233:
functioning pervasive developmental
- Page 234:
P.V.P.: 10 €MINISTERIODE SANIDAD,